A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
Phase 2
Completed
- Conditions
- diabetestype 2 diabetes mellitus10012653
- Registration Number
- NL-OMON34301
- Lead Sponsor
- Hanmi Pharmaceutical Company Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
Type 2 diabetes mellitus,
18 - 75 years,
BMI 25 - 40 kg/m2
Non-smoker of light smoker (inclusive)
Exclusion Criteria
Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters blood in the 10 months preceding the start of the study.
Use of insuline for diabetes in the past.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method